In this article, published in Genetic Engineering and Biotechnology News, Matthew Majewski discusses three alternative reimbursement models to address the pricing challenges payers and manufacturers face to provide patient access to high-cost curative therapies.
To read the full article, click here.
Articles
Preparing US healthcare insurance for high-cost curative therapies
May 22, 2019
Key contacts
Upcoming events
Swiss Biotech Day 2026
CRA is a proud sponsor of the premier global biotechnology conference for life sciences professionals, fostering international collaboration and impactful...
Informa: EU Pharmaceutical Law Forum 2026
CRA is a proud sponsor the event featuring authority insights from the EU Commission, Competition Authorities, EMA and leading pharmaceutical...